- Benzinga
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating Carvykti (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. In simple words, the study compared Carvykti, a treatment for multiple myeloma, to other stan
- Benzinga
Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
A New Jersey federal judge has dismissed a lawsuit brought by a Johnson & Johnson (NYSE:JNJ) subsidiary against Dr. Jacqueline Moline, who published a paper linking talc-based consumer products to cancer. The court found that Moline’s research was neither fraudulent nor libelous, reaffirming her free speech rights under the First Amendment. U.S. District Judge Georgette Castner ruled that Moline did not engage in fraud, libel, or false advertising when she published a 2020 paper concluding that
- Motley Fool
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years.
